18F-FDG PET in malignant lymphoma: significance of positive findings

[1]  Maria A. Rodriguez,et al.  Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease , 2004, American journal of clinical oncology.

[2]  Mithat Gonen,et al.  Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  F. Bénard,et al.  Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  S. Reske.  PET and restaging of malignant lymphoma including residual masses and relapse , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  M. O'Doherty,et al.  Limitations of PET for imaging lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. O'Doherty,et al.  Positron emission tomography in the management of lymphomas: a summary , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  P. Hoskin.  PET in lymphoma: what are the oncologist's needs? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Patrick Dupont,et al.  [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  M. O'Doherty,et al.  Positron emission tomography in the management of lymphomas. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  D. Costa,et al.  Challenging cases and diagnostic dilemmas: case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[12]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  N. Avril,et al.  Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Kostakoglu,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? , 2000, European Journal of Nuclear Medicine.

[15]  M. Schwaiger,et al.  Positron Emission Tomography in Diagnosis and Therapy Monitoring of Patients with Lymphoma. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[16]  A. Belakhlef,et al.  False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  Ludwig G. Strauss,et al.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.

[18]  M. Schwaiger,et al.  PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  R L Wahl,et al.  Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.